LRRK2 and Parkinson disease: These tools have allowed the advancement of LRRK2 kinase inhibitors through preclinical testing, with thee small molecule inhibitors (DNL201, DNL151, ClinicalTrials.gov Identifiers NCT04557800, NCT05119790, NCT04056689, NCT05005338, NCT05418673, NCT05348785, NCT05229562, NCT04551534, NCT03710707, and NEU-723 ClinicalTrials.gov Identifier NCT05633745, note BIIB122 is an alternate name for DNL151) and one anti-sense oligonucleotide (BIIB094, ClinicalTrials.gov Identifier NCT03976349) in clinical trials as potential treatments for PD.